CHIKV-IN-2 是一种针对基孔肯雅病毒 (CHIKV) 的有效抑制剂,具有出色的细胞抗病毒活性 (EC90=270 nM) 和改善的肝微粒体稳定性。CHIKV-IN-2 对细胞靶二氢乳清酸脱氢酶 (DHODH) 表现出抑制活性。
生物活性 | CHIKV-IN-2 is a potent inhibitor againstChikungunya virus (CHIKV), with excellent cellular antiviral activity (EC90=270 nM) and improved liver microsomal stability. CHIKV-IN-2 shows inhibitory activity against a cellular targetDihydroorotate Dehydrogenase(DHODH), which interacts with various viruses and regulate their replication via depleting intracellular pyrimidine pools[1]. |
IC50& Target | EC90: 270 nM (Chikungunya virus)[1] Dihydroorotate Dehydrogenase[1] |
体外研究 (In Vitro) | CHIKV-IN-2 (compound 8q) is a potent pan-alphavirus inhibitor, with EC90s of 0.85-2.5 μM for CHIKV clinical isolates and attenuated vaccine strains[1]. CHIKV-IN-2 is active against alphavirus VEEV (EC90=0.40 μM) as well as flaviviruses such as West Nile Virus (WNV, EC90=0.20 μM) and Dengue Virus Strain-2 (DENV-2, EC90=0.60 μM)[1].
|
体内研究 (In Vivo) | CHIKV-IN-2 (compound 8q) (80 mg/kg; i.p. twice a day for 3 days) significantly decreases infectious CHIKV dissemination to other tissues of mice[1]. CHIKV-IN-2 (40 mg/kg; p.o., i.p., s.c.) exhibits moderate bioavailability (F=41%, 43%, 4%), terminal elimination half-life (t1/2=9.9, 18.5, 18.6 h) and Cmax(642, 858, 90 ng/mL) in mice[1]. CHIKV-IN-2 (1 mg/kg; i.v.) exhibits terminal elimination half-life (t1/2= 2.02 h) and AUC (497 hong/mL) in mice[1].
Animal Model: | Female and male C57BL/6 mice[1] | Dosage: | 80 mg/kg | Administration: | I.p. twice a day for 3 days | Result: | Failed to inhibit virus loads at the site of infection. Decreased virus dissemination to other tissues. |
Animal Model: | Male C57BL/6 mice were challenged with CHIKV in the right footpad[1] | Dosage: | 1 mg/kg for i.v. and 40 mg/kg for p.o., i.p., s.c. (Pharmacokinetic Analysis) | Administration: | I.v., p.o., i.p., s.c. | Result: | I.v.: t1/2= 2.02 h; AUC=497 hong/mL. P.o.: F=41%; t1/2=9.9 h; Cmax=642 ng/mL. I.p.: F=43%; t1/2=18.5 h; Cmax=858 ng/mL. S.c.: F=4%; t1/2=18.6 h; Cmax=90 ng/mL. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 100 mg/mL(275.89 mM;Need ultrasonic) 配制储备液 1 mM | 2.7589 mL | 13.7946 mL | 27.5893 mL | 5 mM | 0.5518 mL | 2.7589 mL | 5.5179 mL | 10 mM | 0.2759 mL | 1.3795 mL | 2.7589 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (6.90 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.90 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (6.90 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.90 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (6.90 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.90 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|